Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT07310420 · Advanced Breast Cancer
NCT05831878 · Advanced Breast Cancer
NCT06595563 · HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
NCT06997029 · Advanced Solid Tumor, Advanced Breast Cancer, and more
Research Site
Chiba
Research Site
Fukuoka
Research Site
Nagoyata
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions